Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054635 | 0.79 | HTR2A (0.37) | PRKACAPRKACGPRKACBHTR2B | |
| SCHEMBL11138422 | 0.79 | HTR2C (0.43) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL29748038 | 0.79 | HTR2C (0.43) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL28822767 | 0.77 | PRKACA (0.34) | PRKACAPRKACGPRKACBCTSKCSNK1D | |
| SCHEMBL28839278 | 0.76 | MEN1 (0.42) | — | |
| SCHEMBL23136984 | 0.76 | PRKACA (0.45) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL30463847 | 0.76 | PRKACA (0.45) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL20319860 | 0.76 | TAAR1 (0.38) | PRKACAPRKACGPRKACBSLC6A2HTR2B | |
| SCHEMBL24005407 | 0.76 | PRKACA (0.36) | PRKACAPRKACGPRKACBSLC6A2ADRA1A | |
| SCHEMBL1177526 | 0.75 | CTSB (0.36) | PRKACAPRKACGPRKACBSLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533796-B1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| CN-109890820-B | Aminopyrazolopyrimidine compounds as neurotrophin tyrosine kinase receptor inhibitors | 正大天晴药业集团股份有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-111163766-A | AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2020-05-15 | — | — | CN | disclosed |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3533796-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| US-9663525-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160244455-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-2571872-B1 | COMPOUNDS | TREHERNE JOHNATHAN MARK (GB) | 2014-12-31 | — | — | EP | disclosed |
| EP-2571872-A1 | COMPOUNDS | BTG International Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| EP-2571856-A1 | COMPOUNDS | BTG International Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011144578-A1 | COMPOUNDS | SENEXIS LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144577-A1 | COMPOUNDS | SENEXIS LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | NTRK2, BDNF, NTRK1 | PRKACA 227/4885PRKACG 366/4885PRKACB 389/4885 |
| US-20160244455-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | PRKACA 1865/4885PRKACG 2123/4885PRKACB 1999/4885 |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | NTRK2, BDNF, NTRK1 | PRKACA 227/4885PRKACG 366/4885PRKACB 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.